International Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136103) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants' on Aug. 15.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: AbbVie

Condition: Healthy Volunteers

Intervention: Drug: ABBV-277

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: August 18, 2025

Target Sample Size: 40

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07136103

P...